Atlas Trials

Lanzhou Institute of Biological Products Co., Ltd

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Lanzhou Institute of Biological Products Co., Ltd

RecordFirmDate
A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (NCT07445815)Lanzhou Institute of Biological Products Co., Ltd2026-01-31
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection (NCT07149454)Lanzhou Institute of Biological Products Co., Ltd2025-08-18
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL (NCT05557903)Lanzhou Institute of Biological Products Co., Ltd2021-12-20
A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) (NCT02786407)Lanzhou Institute of Biological Products Co., Ltd2016-03-01
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine (NCT02481232)Lanzhou Institute of Biological Products Co., Ltd2015-06-01
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine (NCT02291380)Lanzhou Institute of Biological Products Co., Ltd2014-09-01
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity (NCT02280083)Lanzhou Institute of Biological Products Co., Ltd2014-07-01

Track Lanzhou Institute of Biological Products Co., Ltd automatically

Every clearance here is in the API, with alerts when new ones post.